tosylated farnesanol | 68985-16-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: tosylated farnesanol
• 英文别名: (3RS,7RS)-3,7,11-trimethyldodecyl p-toluenesulphonate；3,7,11-trimethyl-dodecyl p-toluene sulfonate；3,7,11-trimethyldodecyl tosylate；3,7,11-trimethyldodecyl 4-methylbenzenesulfonate
• CAS: 68985-16-0
• 化学式: C₂₂H₃₈O₃S
• 分子量: 382.608
• InChiKey: RTNWYLBJPXUIFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8
• 重原子数：
  26
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  tosylated farnesanol 在 Rhodococcus sp. BPM 1613 lithium aluminium tetrahydride 作用下， 生成 (2R/S,6R/S,10R/S)-2,6,10-trimethyldodecan-1-ol
  参考文献：
  名称：

  Nakajima, Kenji; Sato, Akio; Takahara, Yoshimasa, Agricultural and Biological Chemistry, 1985, vol. 49, # 7, p. 1993 - 2002

  摘要：

  DOI：
• 作为产物：
  描述：

  3,7,11-三甲基-1-十二烷醇 、 对甲苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以93%的产率得到tosylated farnesanol
  参考文献：
  名称：

  Eine neue Methode zur立体化学分析fenkettiger萜类化合物Carbonyl-Verbindungen，† ‡

  摘要：

  无环萜烯基羰基化合物立体化学分析的新方法

  DOI：

  10.1002/hlca.19900730432

文献信息

• Pyrazolo[4,3-d]pyrimidine derivative, process for its production,
  申请人：Nissan Chemical Industries Ltd.

  公开号：US04654348A1

  公开（公告）日：1987-03-31

  A pyrazolo[4,3-d]pyrimidine derivative having the formula: ##STR1## wherein R.sup.1 is lower alkyl or phenyl, R.sup.2 is --A--CO.sub.2 R.sup.21 (wherein A is alkylene having from 1 to 10 carbon atoms which is unsubstituted or substituted by alkyl having from 1 to 3 carbon atoms; and R.sup.21 is lower alkyl having from 1 to 4 carbon atoms), --CH.sub.2 CO-phenyl, a saturated or unsaturated, straight chain or branched aliphatic group having from 3 to 16 carbon atoms, phenyl-lower alkyl, --CH.sub.2 CN, chloro substituted phenyl-lower alkyl or ##STR2## (wherein R.sup.22 is hydrogen or lower alkyl), and R.sup.3 is a saturated or unsaturated, straight chain or branched aliphatic group having from 2 to 22 carbon atoms, phenyl-lower alkyl, benzyloxy substituted phenyl-lower alkyl, lower alkyl substituted or unsubstituted 2-(phenylmethyloxy)ethyl, cyclohexylcyclohexyl, methylcyclohexyl, 3-thia-n-heptyl, 3,6-dioxa-n-decyl, 4-oxo-n-pentyl or 2-hydroxyethyl. Intermediates and processes of making the compounds of formula I are also disclosed. The compounds of formula I are useful as antihyperlipidemic agents.

  一种具有以下结构的吡唑并[4,3-d]嘧啶衍生物：##STR1##其中R.sup.1是较低的烷基或苯基，R.sup.2是--A--CO.sub.2R.sup.21（其中A是具有1至10个碳原子的未取代或取代的烷基，取代基为具有1至3个碳原子的烷基；R.sup.21是具有1至4个碳原子的较低烷基），--CH.sub.2CO-苯基，具有3至16个碳原子的饱和或不饱和、直链或支链脂肪族基团，苯基-较低烷基，--CH.sub.2CN，氯取代的苯基-较低烷基或##STR2##（其中R.sup.22是氢或较低烷基），R.sup.3是具有2至22个碳原子的饱和或不饱和、直链或支链脂肪族基团，苯基-较低烷基，苄氧基取代的苯基-较低烷基，取代或未取代的2-(苯基甲氧基)乙基，环己基环己基，甲基环己基，3-硫代-n-庚基，3,6-二氧-n-癸基，4-氧代-n-戊基或2-羟乙基。还公开了制备式I化合物的中间体和工艺。式I化合物可用作抗高脂血症药物。
• Type II Cubic Liquid Crystal Composition
  申请人：Hatoh Masakatsu

  公开号：US20080113923A1

  公开（公告）日：2008-05-15

  A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

  一种立方液晶组合物，包括至少一种具有以下通式（1）并具有0.65至0.95的IV/OV值的两性化合物和水或水性介质：其中R代表亲水基团；X和Y各自独立地表示氢原子或一起形成氧原子；n为0至4的整数；m为0至3的整数。
• Type II cubic liquid crystal composition
  申请人：National Institute of Advanced Industrial Science and Technology

  公开号：US07846903B2

  公开（公告）日：2010-12-07

  A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

  一种立方液晶组合物，包括至少一种具有下列一般式(1)和IV/OV值为0.65至0.95的两亲性化合物和水或水性介质： 其中，R代表亲水基团；X和Y各自独立地代表氢原子或共同形成氧原子；n为0至4的整数；m为0至3的整数。
• Pyrazolo[4,3-d] pyrimidine derivative process for its production antihyperlipidemic agent containing it, its intermediate, and process for the production of the intermediate
  申请人：NISSAN CHEMICAL INDUSTRIES LTD.

  公开号：EP0157415A2

  公开（公告）日：1985-10-09

  A pyrazolo[4,3-d]pyrimidine derivative having the formula: wherein R1 is lower alkyl, phenyl or substituted phenyl, R2 is -A-CO2R21 (wherein A is alkylene having from 1 to 3 carbon atoms which is unsubstituted or substituted by methyl, and R21 is lower alkyl having from 1 to 4 carbon atoms), -CH2CO-phenyl, a saturated or unsaturated, straight chain or branched aliphatic group having from 3 to 16 carbon atoms, phenyl-lower alkyl, -CH2CN, substituted phenyl-lower alkyl, cyclohexylcyclohexyl, methylcyclohexyl, 4-thia-n-heptyl, 3,6-dioxa-n-octyl, 4-oxo-n-pentyl or (wherein R22 is hydrogen or lower alkyl), and R3 is a saturated or unsaturated, straight chain or branched aliphatic group having from 2 to 22 carbon atoms, phenyl-lower alkyl, substituted phenyl-lower alkyl, substituted or unsubstituted phenyl-methyloxyethyl or 2-hydroxyethyl.

  一种吡唑并[4,3-d]嘧啶衍生物，其式如下 其中 R1 是低级烷基、苯基或取代苯基，R2 是-A-CO2R21（其中 A 是具有 1 至 3 个碳原子的亚烷基，未被取代或被甲基取代，R21 是具有 1 至 4 个碳原子的低级烷基），-CH2CO-苯基、具有 3 至 16 个碳原子的饱和或不饱和、直链或支链脂肪族基团、苯基低级烷基、-CH2CN、取代苯基低级烷基、环己基环己基、甲基环己基、4-硫杂-n-庚基、3,6-二氧杂-n-辛基、4-氧代-n-戊基，或 (其中 R22 为氢或低级烷基），R3 为具有 2 至 22 个碳原子的饱和或不饱和、直链或支链脂族基团、苯基-低级烷基、取代的苯基-低级烷基、取代或未取代的苯基-甲基羟乙基或 2-羟乙基。
• TYPE II CUBIC LIQUID CRYSTAL COMPOSITION
  申请人：National Institute of Advanced Industrial Science and Technology

  公开号：EP1813287A1

  公开（公告）日：2007-08-01

  A cubic liquid crystal composition comprising at least one amphiphilic compound having the following general formula (1) and having an IV/OV value of 0.65 to 0.95, and water or an aqueous medium: wherein R represents a hydrophilic group; X and Y each independently represent a hydrogen atom or together form an oxygen atom; n is an integer of 0 to 4; and m is an integer of 0 to 3.

  一种立方液晶组合物，包含至少一种具有以下通式（1）且 IV/OV 值为 0.65 至 0.95 的两性化合物，以及水或水性介质： 其中 R 代表亲水基团；X 和 Y 各自独立地代表氢原子或共同构成氧原子；n 是 0 至 4 的整数；m 是 0 至 3 的整数。